BRPI1010885A2 - motivos de modificação química para inibidores mirna e miméticos. - Google Patents
motivos de modificação química para inibidores mirna e miméticos.Info
- Publication number
- BRPI1010885A2 BRPI1010885A2 BRPI1010885A BRPI1010885A BRPI1010885A2 BR PI1010885 A2 BRPI1010885 A2 BR PI1010885A2 BR PI1010885 A BRPI1010885 A BR PI1010885A BR PI1010885 A BRPI1010885 A BR PI1010885A BR PI1010885 A2 BRPI1010885 A2 BR PI1010885A2
- Authority
- BR
- Brazil
- Prior art keywords
- mirna
- chemical modification
- modification motifs
- mimetic inhibitors
- mimetic
- Prior art date
Links
- 238000007385 chemical modification Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108091070501 miRNA Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18503309P | 2009-06-08 | 2009-06-08 | |
| PCT/US2010/037821 WO2010144485A1 (en) | 2009-06-08 | 2010-06-08 | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010885A2 true BRPI1010885A2 (pt) | 2015-09-22 |
Family
ID=43309198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010885A BRPI1010885A2 (pt) | 2009-06-08 | 2010-06-08 | motivos de modificação química para inibidores mirna e miméticos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20120148664A1 (pt) |
| EP (1) | EP2440566A4 (pt) |
| JP (1) | JP2012529295A (pt) |
| KR (1) | KR20120047892A (pt) |
| CN (1) | CN102803284B (pt) |
| AU (1) | AU2010258875A1 (pt) |
| BR (1) | BRPI1010885A2 (pt) |
| CA (1) | CA2765129A1 (pt) |
| EA (1) | EA022757B1 (pt) |
| GE (1) | GEP20156329B (pt) |
| MA (1) | MA33488B1 (pt) |
| MX (1) | MX2011013176A (pt) |
| NZ (1) | NZ597078A (pt) |
| SG (1) | SG176716A1 (pt) |
| UA (1) | UA105390C2 (pt) |
| WO (1) | WO2010144485A1 (pt) |
| ZA (1) | ZA201109319B (pt) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| WO2011106104A2 (en) | 2010-02-26 | 2011-09-01 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets |
| US20120116381A1 (en) | 2010-11-05 | 2012-05-10 | Houser Kevin L | Surgical instrument with charging station and wireless communication |
| EP2652151A2 (en) | 2010-12-15 | 2013-10-23 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| CN102643807B (zh) * | 2011-02-18 | 2015-06-03 | 中国科学院上海药物研究所 | 人miR-484的反义寡聚核苷酸及其应用 |
| AU2012246822B2 (en) * | 2011-04-22 | 2017-05-25 | Biomarin Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1) |
| MX393138B (es) | 2011-04-25 | 2025-03-24 | Sanofi Sa | Compuestos de microarn y metodos para modular la actividad de mir-21. |
| WO2012149646A1 (en) * | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| WO2012153135A1 (en) * | 2011-05-09 | 2012-11-15 | University Of Glasgow | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
| EP2763703B1 (en) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| PT2841578T (pt) | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| MY173600A (en) | 2012-04-25 | 2020-02-08 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| CN102703456B (zh) * | 2012-05-15 | 2014-04-02 | 武汉生命之美科技有限公司 | DAPK3基因hsa-miR-20a的作用靶位点 |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| CA2902623A1 (en) | 2013-03-15 | 2014-09-25 | MiRagen Therapeutics, Inc. | Locked nucleic acid inhibitor of mir-145 and uses thereof |
| JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法 |
| CN103290011B (zh) * | 2013-05-16 | 2015-09-16 | 南京市妇幼保健院 | 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-29c及其应用 |
| CN103667441B (zh) * | 2013-09-10 | 2016-10-19 | 山西医科大学第一医院 | 一种Hsa-miR-145-5p试剂盒及其成熟体模拟物的应用 |
| GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
| CN104083761A (zh) * | 2014-06-25 | 2014-10-08 | 北京大学第三医院 | microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用 |
| MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| US10889813B2 (en) * | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
| WO2017043490A1 (ja) * | 2015-09-07 | 2017-03-16 | 協和発酵バイオ株式会社 | 自然免疫誘導効果が増強した二重鎖リボ核酸 |
| EP3426781B1 (en) * | 2016-03-07 | 2024-06-26 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Micrornas and methods of their use |
| EP3449001B1 (en) * | 2016-04-29 | 2021-12-08 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| JP6842779B2 (ja) * | 2016-10-31 | 2021-03-17 | 国立大学法人岐阜大学 | 二本鎖核酸分子、およびその用途 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US12691135B2 (en) | 2018-03-14 | 2026-07-28 | Beth Israel Deaconess Medical Center | Inhibitors of micro-RNA 22 |
| CN111918968B (zh) * | 2018-03-14 | 2023-11-24 | 贝斯以色列女执事医疗中心 | Micro-RNA 22的抑制剂 |
| TWI854980B (zh) | 2018-05-08 | 2024-09-11 | 美商雷格勒斯治療公司 | 用於調節mir-122之微小rna化合物及方法 |
| US11015197B2 (en) | 2018-08-29 | 2021-05-25 | Korea Institute Of Science And Technology | Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite |
| CN116096890A (zh) | 2020-04-02 | 2023-05-09 | 米雷楚莱股份有限公司 | 使用工程化寡核苷酸的靶向抑制 |
| JP7825881B2 (ja) * | 2020-07-23 | 2026-03-09 | ヨハン ヴォルフガング ゲーテ－ウニヴェルズィテート フランクフルト | 心不全治療のためのｍｉＲＮＡのコンビナトリアル阻害 |
| WO2023014972A2 (en) * | 2021-08-06 | 2023-02-09 | New York R&D Center For Translational Medicine And Therapeutics, Inc. | Microrna compositions and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| CN101426912A (zh) * | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
| WO2008109373A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| WO2009062169A2 (en) * | 2007-11-09 | 2009-05-14 | The Board Of Regents Of The University Of Texas System | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
-
2010
- 2010-06-08 MA MA34505A patent/MA33488B1/fr unknown
- 2010-06-08 GE GEAP201012527A patent/GEP20156329B/en unknown
- 2010-06-08 MX MX2011013176A patent/MX2011013176A/es active IP Right Grant
- 2010-06-08 EP EP20100786712 patent/EP2440566A4/en not_active Withdrawn
- 2010-06-08 KR KR1020127000345A patent/KR20120047892A/ko not_active Ceased
- 2010-06-08 UA UAA201200188A patent/UA105390C2/ru unknown
- 2010-06-08 CA CA2765129A patent/CA2765129A1/en not_active Abandoned
- 2010-06-08 NZ NZ597078A patent/NZ597078A/xx not_active IP Right Cessation
- 2010-06-08 EA EA201171493A patent/EA022757B1/ru not_active IP Right Cessation
- 2010-06-08 BR BRPI1010885A patent/BRPI1010885A2/pt not_active IP Right Cessation
- 2010-06-08 US US13/377,076 patent/US20120148664A1/en not_active Abandoned
- 2010-06-08 WO PCT/US2010/037821 patent/WO2010144485A1/en not_active Ceased
- 2010-06-08 CN CN201080035109.9A patent/CN102803284B/zh not_active Expired - Fee Related
- 2010-06-08 SG SG2011090529A patent/SG176716A1/en unknown
- 2010-06-08 AU AU2010258875A patent/AU2010258875A1/en not_active Abandoned
- 2010-06-08 JP JP2012515076A patent/JP2012529295A/ja active Pending
-
2011
- 2011-12-19 ZA ZA2011/09319A patent/ZA201109319B/en unknown
-
2013
- 2013-08-22 US US13/973,594 patent/US20140066491A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2440566A1 (en) | 2012-04-18 |
| GEP20156329B (en) | 2015-07-27 |
| SG176716A1 (en) | 2012-01-30 |
| NZ597078A (en) | 2013-11-29 |
| EP2440566A4 (en) | 2013-10-16 |
| MX2011013176A (es) | 2012-04-30 |
| EA201171493A1 (ru) | 2012-06-29 |
| CA2765129A1 (en) | 2010-12-16 |
| US20140066491A1 (en) | 2014-03-06 |
| UA105390C2 (ru) | 2014-05-12 |
| CN102803284B (zh) | 2015-11-25 |
| US20120148664A1 (en) | 2012-06-14 |
| CN102803284A (zh) | 2012-11-28 |
| EA022757B1 (ru) | 2016-02-29 |
| WO2010144485A1 (en) | 2010-12-16 |
| JP2012529295A (ja) | 2012-11-22 |
| AU2010258875A1 (en) | 2012-01-19 |
| ZA201109319B (en) | 2013-02-27 |
| MA33488B1 (fr) | 2012-08-01 |
| KR20120047892A (ko) | 2012-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020024I2 (el) | Αναστολεiς βητα-λακταμασων | |
| BRPI0815725A2 (pt) | Métodos para detecção de oligonucleotídeos | |
| SG176716A1 (en) | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS | |
| BRPI1013219A2 (pt) | método para o alvejamento-branqueamento enzimático têxtil | |
| BRPI0918970A2 (pt) | algoritmo para projeto de inibidores irreversíveis | |
| BRPI1011309A2 (pt) | suporte para cartões | |
| BRPI1011201A2 (pt) | métodos e sistemas de cartão de cupom. | |
| BRPI0916787A2 (pt) | artigo, e, método para fabricar um artigo | |
| BRPI0906854A2 (pt) | dispositivo para detectar objetos do espaço. | |
| BRPI1014035A2 (pt) | método para contracepção. | |
| PT2368118E (pt) | Biomarcadores para inibidores com atividade anti-angiogénica | |
| BRPI1006251A2 (pt) | diferencial e bloco de reação para um diferencial | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0915492A2 (pt) | sistemas e métodos para transferir valores | |
| BRPI0819448A2 (pt) | Método para transações seguras | |
| BRPI1011523A2 (pt) | processamento de gás de hidrocarboneto. | |
| PT3957754T (pt) | Método para detetar o vírus chikungunya | |
| BRPI1011786A2 (pt) | métodos para codificação artimética. | |
| BRPI1010124A2 (pt) | plugue para expedição, sistema de vadação e kit de plugue para expedição | |
| BRPI0807853A2 (pt) | Prendedor para vestuário. | |
| ES1066983Y (es) | Estuche para extracciones domiciliarias | |
| BR112012000911A2 (pt) | biomarcador. | |
| ES1073526Y (es) | Almohada. | |
| EP2497407A4 (en) | RACHENWEITUNGSVORRICHTUNG | |
| BRPI1011526A2 (pt) | processamento de gás de hidrocarbonetos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |